Enriched siRNA Therapeutic Pipeline
Sirnaomics technology developments are focused on (1) enhancement of the potency of active pharmaceutical ingredient (API) using multi-targeted small interfering RNA (siRNA) cocktail; (2) improvement of the API in vivo delivery using clinical viable synthetic polymeric and lipid nanoparticles. The siRNA cocktail is potentially more effective since The target gene knockdown may not affect downstream protein synthesis due to redundancy of genes within a pathway. Along with tissue specific carriers to deliver RNAi into cells, the technology has the competitive advantage of being more potent and more specific in activity.
With solid foundation of the technological platforms and intellectual properties, Sirnaomics has established an enriched product pipeline of siRNA therapeutics which is a true combination of “low-hanging fruit” types and “blockbuster drug” potentials. Even though the local and topical delivery facilitated siRNA therapeutics may allow us the early success, the systemic delivery based siRNA therapeutics are still facing tremendous challenge as viable therapeutics agents.